Neoadjuvant chemoradiation is currently standard of care in stage II–III rectal cancer, resulting in tumor downstaging for patients with treatment-responsive disease. However, the prognosis of the downstaged patient remains controversial. This work critically analyzes the relative contribution of pre- and post-therapy staging to the anticipated survival of downstaged patients.

中文翻译：

---

临床与病理分期对接受新辅助治疗的直肠癌患者的预后价值

目前，新辅助放化疗是II-III期直肠癌的治疗标准，导致具有治疗反应性疾病的患者的肿瘤分期降低。但是，降级患者的预后仍存在争议。这项工作批判性地分析了治疗前和治疗后分期对晚期患者预期生存的相对贡献。